chronic urticaria - HEALTHY
Markets Insider: Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU) Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU) Sanofi (ENXTPA:SAN) secures European Commission approval to expand Dupixent use to children with chronic spontaneous urticaria. The company becomes the Canadian market authorization holder for ... Markets Insider: Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria Health on MSN: What living with chronic spontaneous urticaria (CSU) looks like for one couple What living with chronic spontaneous urticaria (CSU) looks like for one couple Among patients with new-onset urticaria, 75% recovered within a week, whereas 17% progressed to chronic urticaria, and higher age at onset, elevated BMI, and early prednisolone use were associated ...
Context Explanation
The American Journal of Managed Care: Patients With Chronic Urticaria May Face Higher Risk of Metabolic Syndrome Chronic urticaria patients may have a higher risk of metabolic syndrome, with a pooled prevalence of 25.2% and an odds ratio of 1.59. The evidence is limited by significant bias and inconsistency, ... PharmiWeb: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria